New DTU tablet can pave the way for oral insulin

With a new type of tablet, scientists at the Technical University of Denmark (DTU) hope to do what Novo Nordisk was not capable of – to deliver insulin orally so diabetes patients will not need to inject themselves. Professor Anja Boisen reveals that DTU has already initiated a dialogue with a number of drug companies, including Novo.

The DTU pill consists of an outer sheath protecting the microcapsules untill they reach the intestine. Photo: Jesper Scheel, DTU Nanotech

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Dansk biotekboss rejser 91 mio til at udfordre Novo Nordisk

Et amerikansk biotekselskab, som er grundlagt af en dansk molekylærbiolog, har rejst 91 mio. kr. til at fremme programmer inden for diabetes, fedme og fedtlever, herunder et "transformativt" diabeteslægemiddel rettet mod biologiske mål, som Novo Nordisk også arbejder med.

Related articles